UMnyango Wezizwe Zonke

Ngo-Ephreli 25, 2025, i-InnoCare Pharma yamemezela ukuthi isizukulwane sayo esisha se-pan-TRK inhibitor zurletrectinib (ICP-723) sinikezwe ukubuyekezwa okubalulekile yi-Center for Drug Evaluation (CDE) ye-China National Medical Products Administration (NMPA), eyamukela i-New Drug Application (NDA) ye-z...Funda kabanzi»

Ngo-Ephreli 25, 2025, i-Innovent Biologics imemezela ukuthi i-National Medical Products Administration (NMPA) yaseShayina ivumile i-New Drug Application (NDA) ye-limertinib njengokwelashwa kokuqala kweziguli ezindala ezine-metastatic noma i-metastatic non-small cell lung cancer (NSCLC) harbo...Funda kabanzi»

Ngomhlaka-23 kuMbasa, i-penpulimab ka-Akeso yathola imvume ye-Food and Drug Administration ene-cisplatin noma i-carboplatin kanye ne-gemcitabine yokwelashwa kokuqala kwabantu abadala abane-carcinoma ye-nasopharyngeal ephindaphindayo noma esakazeka kalula (i-NPC). I-FDA iphinde yagunyaza i-penpulimab-kcqx njengesono...Funda kabanzi»

NgoMashi 16, 2025, i-Akeso yamemezela ukuthi i-antibody yayo entsha, ezenzele ngokwayo, i-anti-PD-1 monoclonal, i-penpulimab, ivunyelwe ngokusemthethweni yi-National Medical Products Administration (NMPA) yokwelapha umdlavuza we-nasopharyngeal ophindaphindayo noma osakazeka kalula (NPC) ngokuhlanganiswa ...Funda kabanzi»

Ngo-Ephreli 24, 2025, i-GenFleet Therapeutics yamemezela ukuthi i-US Food and Drug Administration (FDA) ivumile ukusetshenziswa komuthi omusha (IND) we-GFH375/VS-7375, umuthi womlomo we-KRAS G12D (ON/OFF), wokuhlolwa kwezokwelapha iziguli ezine-tumor eqinile ezithuthukile ezine-mutation ye-KRAS G12D. Ucwaningo...Funda kabanzi»

Ngo-Ephreli 17, 2025, i-Hansoh Pharmaceutical imemezela ukuthi i-B7-H3-target antibody-drug conjugate (ADC) HS-20093 yeQembu eyazithuthukisa ngokwayo ukuze ijovwe ithole imvume yokufakwa njengoMuthi Oqokiwe Wokwelapha yi-National Medical Products Administration (NMPA) yaseShayina, ...Funda kabanzi»

Ngomhlaka-15 Ephreli 2025, i-InnoCare Pharma yamemezela ukuthi i-Center for Drug Evaluation (CDE) ye-China National Medical Products Administration (NMPA) yamukele isicelo esisha semithi (NDA) yesizukulwane sayo esisha semithi yokwelapha i-pan-TRK inhibitor zurletrectinib (ICP-723) yokwelapha abantu abadala kanye nentsha...Funda kabanzi»

Muva nje, i-GenFleet imemezele idatha yakamuva yesigaba sesi-2 socwaningo lwe-KROCUS, i-fulzerasib (GFH925, i-KRAS G12C inhibitor) ngokuhlanganiswa ne-cetuximab yokwelashwa komdlavuza wamaphaphu ongewona amaseli amancane (i-NSCLC) komugqa wokuqala, esifinyezweni esisheshayo ekwethulweni okuncane komlomo kwe-European Lung Cancer Conf ka-2025...Funda kabanzi»

I-PLB1004, eyasungulwa yi-Beijing Avistone Biotechnology Co., Ltd., iyi-receptor ye-tyrosine kinase inhibitor (EGFR-TKI) ephephile, ekhetha kakhulu futhi esebenza kahle engasetshenziswa ekwelapheni umdlavuza wamaphaphu ongewona amaseli amancane (NSCLC). Ngomhlaka-9 Ephreli 2025, i-National Medical Products Admi...Funda kabanzi»

NgoMashi 13, 2025, iphephandaba lamazwe ngamazwe i-Nature Medicine lashicilela isivivinyo se-MediLink se-B7-H3 esiqondisa i-antibody drug conjugate (ADC) YL201 Phase 1/1b. Isivivinyo sasihlanganisa ingxenye yokwanda komthamo (isigaba 1) kanye nengxenye yokwandiswa komthamo (isigaba 1b). Iziguli ezingu-312 zibhalisiwe kulo lonke...Funda kabanzi»

NgoMashi 21, 2025, i-Immunofoco yamemezela ukuthi ukwelashwa kwayo kweseli ye-CAR-T okuqondiswe ku-EpCAM, i-IMC001, okuthuthukiswe ngokuzimela, kunikezwe imvume yi-Center for Drug Evaluation (CDE) ngaphansi kwe-National Medical Products Administration (NMPA) eShayina nge-Investigational New Drug yayo yesibili...Funda kabanzi»

NgoMashi 31, 2025, i-Innovent Biologics yamemezela ukuthi i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA) yaseShayina inikeze i-Breakthrough Therapy Designation (BTD) ye-IBI363, iphrotheni yokuqala ye-PD-1/IL-2α-bias bispecific antibody fusion protein, njenge-monotherapy ye...Funda kabanzi»